Introduction: In the INBUILD trial in patients with progressive fibrosing ILDs other than IPF, nintedanib reduced the rate of decline in FVC with a safety profile characterised mainly by gastrointestinal events. Patients who completed the INBUILD trial could enter the open-label extension trial INBUILD-ON.
No takes yet. Share an insight, caveat, or question.
Bonella et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: